335 related articles for article (PubMed ID: 12702987)
21. Reinforced interferon alpha-2b and ribavirin is more effective than standard combination therapy in the retreatment of chronic hepatitis C previously nonresponsive to interferon: a randomized trial.
Poynard T; Marcellin P; Bissery A; Myers RP; Moussalli J; Degos F; Dhumeaux D; Riachi G; Bronowicki JP; Brissot P; Buffet C; Serfaty L; Naveau S; Sogni P; Beaugrand M; Gayno S; Larrey D; Samuel D; Eugene C; Pol S; Bedossa P; Daurat V; Chaumet-Riffaud P;
J Viral Hepat; 2003 May; 10(3):197-204. PubMed ID: 12753338
[TBL] [Abstract][Full Text] [Related]
22. Treatment effects and predictors of a 24-week course of interferon alpha-2b plus ribavirin combination therapy for patients with chronic hepatitis C.
Tomimatsu M; Aizawa Y; Chuganji Y; Ishizuka H; Fujita Y; Aizawa R; Abe H; Matsuda T; Itou Y; Nakanishi H; Ushiyama H; Higuchi T; Fujimoto T; Endou H; Iga D; Ohta K; Kuroda H
J Gastroenterol Hepatol; 2006 Jul; 21(7):1177-83. PubMed ID: 16824072
[TBL] [Abstract][Full Text] [Related]
23. A randomized controlled trial of double versus triple therapy with amantadine for genotype 1 chronic hepatitis C in Latino patients.
Méndez-Navarro J; Chirino RA; Corey KE; Gorospe EC; Zheng H; Morán S; Juarez JA; Chung RT; Dehesa-Violante M
Dig Dis Sci; 2010 Sep; 55(9):2629-35. PubMed ID: 19960257
[TBL] [Abstract][Full Text] [Related]
24. Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.
Angelico M; Koehler-Horst B; Piccolo P; Angelico F; Gentile S; Francioso S; Tarquini P; Vecchia RD; Ponti L; Pilleri G; Barlattani A; Grieco A; Soccorsi F; Guarascio P; Demelia L; Sorbello O; Rossi Z; Forlini G; Zaru S; Bandiera F;
Eur J Gastroenterol Hepatol; 2008 Jul; 20(7):680-7. PubMed ID: 18679072
[TBL] [Abstract][Full Text] [Related]
25. Daily or three times a week interferon alfa-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C.
de Lédinghen V; Trimoulet P; Winnock M; Foucher J; Bourlière M; Desmorat H; Canva V; Capron D; Lévy S; Mion F; Mannant PR; Chêne G; Fleury H; Couzigou P; Bernard PH;
J Hepatol; 2002 May; 36(5):672-80. PubMed ID: 11983451
[TBL] [Abstract][Full Text] [Related]
26. Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C.
Brillanti S; Levantesi F; Masi L; Foli M; Bolondi L
Hepatology; 2000 Sep; 32(3):630-4. PubMed ID: 10960460
[TBL] [Abstract][Full Text] [Related]
27. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
[TBL] [Abstract][Full Text] [Related]
28. A randomized, controlled trial of triple antiviral therapy as initial treatment of chronic hepatitis C in HIV-infected patients.
Puoti M; Zanini B; Quinzan GP; Ravasio L; Paraninfo G; Santantonio T; Rollo A; Artioli S; Maggiolo F; Zaltron S; Raise E; Mignani E; Resta F; Verucchi G; Pastore G; Suter F; Carosi G;
J Hepatol; 2004 Aug; 41(2):312-8. PubMed ID: 15288482
[TBL] [Abstract][Full Text] [Related]
29. Quantification of serum hepatitis C virus RNA with daily or standard interferon doses plus ribavirin in nonresponder patients with chronic hepatitis C.
Buti M; Olive G; Stalgis C; Esteban R; Guardi J
Dig Dis Sci; 2000 Apr; 45(4):685-9. PubMed ID: 10759235
[TBL] [Abstract][Full Text] [Related]
30. Interferon alpha-2B and ribavirin in combination for patients with chronic hepatitis C who failed to respond to, or relapsed after, interferon alpha therapy: a randomized trial.
Barbaro G; Di Lorenzo G; Belloni G; Ferrari L; Paiano A; Del Poggio P; Bacca D; Fruttaldo L; Mongiò F; Francavilla R; Scotto G; Grisorio B; Calleri G; Annese M; Barelli A; Rocchetto P; Rizzo G; Gualandi G; Poltronieri I; Barbarini G
Am J Med; 1999 Aug; 107(2):112-8. PubMed ID: 10460040
[TBL] [Abstract][Full Text] [Related]
31. High-dose interferon alpha-2a with ribavirin and amantadine in naïve chronic hepatitis C patients--results of a randomized, prospective, pilot study.
Ullerich H; Avenhaus W; Poremba C; Domschke W; Menzel J
Aliment Pharmacol Ther; 2002 Dec; 16(12):2107-14. PubMed ID: 12452944
[TBL] [Abstract][Full Text] [Related]
32. Amantadine in non-responder patients with chronic hepatitis C: a randomized prospective study.
Palabıyıkoğlu M; Ormeci N; Ekiz F; Beyler AR; Erdem H; Dökmeci A; Ozkan H; Köklü S; Coban S
Hepatogastroenterology; 2012 Sep; 59(118):1911-4. PubMed ID: 22819912
[TBL] [Abstract][Full Text] [Related]
33. Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients.
Taliani G; Gemignani G; Ferrari C; Aceti A; Bartolozzi D; Blanc PL; Capanni M; Esperti F; Forte P; Guadagnino V; Mari T; Marino N; Milani S; Pasquazzi C; Rosina F; Tacconi D; Toti M; Zignego AL; Messerini L; Stroffolini T;
Gastroenterology; 2006 Apr; 130(4):1098-106. PubMed ID: 16618404
[TBL] [Abstract][Full Text] [Related]
34. Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy.
Myers RP; Benhamou Y; Bochet M; Thibault V; Mehri D; Poynard T
AIDS; 2004 Jan; 18(1):75-9. PubMed ID: 15090832
[TBL] [Abstract][Full Text] [Related]
35. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
Fried MW; Shiffman ML; Reddy KR; Smith C; Marinos G; Gonçales FL; Häussinger D; Diago M; Carosi G; Dhumeaux D; Craxi A; Lin A; Hoffman J; Yu J
N Engl J Med; 2002 Sep; 347(13):975-82. PubMed ID: 12324553
[TBL] [Abstract][Full Text] [Related]
36. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group.
Reichard O; Norkrans G; Frydén A; Braconier JH; Sönnerborg A; Weiland O
Lancet; 1998 Jan; 351(9096):83-7. PubMed ID: 9439491
[TBL] [Abstract][Full Text] [Related]
37. Effect of ribavirin and amantadine on early hepatitis C virus RNA rebound and clearance in serum during daily high-dose interferon.
Lake-Bakaar G; Ruffini L; Kuzmic P
Dig Dis Sci; 2003 Jan; 48(1):126-39. PubMed ID: 12645800
[TBL] [Abstract][Full Text] [Related]
38. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study.
Samuel D; Bizollon T; Feray C; Roche B; Ahmed SN; Lemonnier C; Cohard M; Reynes M; Chevallier M; Ducerf C; Baulieux J; Geffner M; Albrecht JK; Bismuth H; Trepo C
Gastroenterology; 2003 Mar; 124(3):642-50. PubMed ID: 12612903
[TBL] [Abstract][Full Text] [Related]
39. Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naïve patients with chronic hepatitis C genotype 1 infection.
Ferenci P; Formann E; Laferl H; Gschwantler M; Hackl F; Brunner H; Hubmann R; Datz C; Stauber R; Steindl-Munda P; Kessler HH; Klingler A; Gangl A;
J Hepatol; 2006 Feb; 44(2):275-82. PubMed ID: 16338019
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of long-term efficacy of interferon alpha-2b and ribavirin in combination in naive patients with chronic hepatitis C: an Italian multicenter experience. Ribavirin-Interferon in Chronic Hepatitis Italian Group Investigators.
Barbaro G; Di Lorenzo G; Soldini M; Giancaspro G; Pellicelli A; Grisorio B; Barbarini G
J Hepatol; 2000 Sep; 33(3):448-55. PubMed ID: 11020001
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
